Skip to content

IVF Outcome Following Progestogen Ovarian Stimulation

Role Of Dydrogesterone Towards Oocyte and Embryo Quality in Polycystic Ovarian Syndrome (PCOS)

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT04175990
Enrollment
155
Registered
2019-11-25
Start date
2018-05-10
Completion date
2019-05-09
Last updated
2019-11-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Clinical Pregnancy Rate, IVF, Oocyte Maturation Defect 1, Ovarian Hyperstimulation

Keywords

progestogen, ovarian stimulation regime, IVF outcome

Brief summary

The new strategy is by using the progestogen to block the luteinizing hormone(LH) surge either endogenous during luteal phase stimulation, or exogenous in the follicular phase i.e progestin primed ovarian stimulation (PPOS). The goal of PPOS is to develop a single dominant follicle. Various types of oral Progestin had been studied before including Medroxyprogesterone Acetate (MPA) and Utrogestan with different dosage. A different study by Wang et al conducted by using MPA to patients with PCOS. The use of MPA is contraindicated in human pregnancy whereas Dydrogesterone had been extensively used worldwide for the treatment of threatened miscarriage as well as luteal support in infertility setting. Previous protocol on PPOS showed inconclusive results. Therefore in this study, Dydrogesterone was used as the Progestin Primed Ovarian hyperstimulation to explore its effect on PCOS women IVF outcome.

Detailed description

This is a prospective controlled cohort study conducted at the Department of Medical Assisted Conception (MAC) unit of the University Kebangsaan Malaysia Medical Centre (UKMMC). From May 2018 through May 2019, women with Polycystic Ovarian Syndrome (PCOS) undergoing IVF/intracytoplasmic sperm insemination(ICSI) regimens for the treatment of infertility were recruited. Patients recruited will then be randomized accordingly using the randomizer software. Group A will be the interventional group and group B will be the control group. Oocyte retrieval will be performed 34-36 hours following the human chorionic gonadotrophin (hCG) trigger. Sperm was obtained on the same day. Mature oocytes will be fertilized with sperm via IVF or ICSI. Fertilized embryos were observed via time laps method and the progress and cleavage were monitored before planning for embryo transfer. Embryo transfer will be performed on day 3 or day 5 after oocyte retrieval. All results will be analyzed using Statistical Package for the Social Sciences(SPSS) version 21 software. Descriptive analysis will be done for demographic data and presented in mean ± Standard deviation (SD). Demographic characteristic between the two groups will be compared with the use of the Mann-Whitney U test. The categorical data was analysed by using Chi-square test for the association of variables. A p-value of 0.05 or less was considered to be significant.

Interventions

started from day 1 of menses till trigger day

Sponsors

National University of Malaysia
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
OTHER
Masking
QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
FEMALE
Age
20 Years to 40 Years
Healthy volunteers
No

Inclusion criteria

* · Aged 20 - 40 years old * Basal serum follicular stimulating hormone(FSH) level of no more than 10 IU/L * Diagnosis of PCOS met using Rotterdam criteria.

Exclusion criteria

* low AMH level (AMH less than 3 ng/ml). * Contraindicated to ovarian stimulation treatment eg: history of severe ovarian hyper stimulation syndrome(OHSS) * Presence of uterine pathology eg: adenomyosis, large uterine fibroid. * Patients who has had poor ovarian stimulation of twice or more.

Design outcomes

Primary

MeasureTime frameDescription
Number of oocyte retrieval30 hour after trigger with HCG 10000 International unit (IU)number of oocyte retrieved
Biochemical pregnancy rate14 days after embryo transferredserum Bhcg more than 5 mol/L
clinical pregnancy rate4 weeks after embryo transferpresence of intrauterine gestational sac

Countries

Malaysia

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026